Erdafitinib for the treatment of urothelial cancer

Analysis of FGFR alterations from circulating tumor DNA (ctDNA) and Tissue in a phase II trial of erdafitinib in urothelial carcinoma (UC).

(2019) Ademi E. Santiago-Walker et al.   JOURNAL OF CLINICAL ONCOLOGY

Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.

(2019) Scott T. Tagawa et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

(2019) Y Fradet et al.   ANNALS OF ONCOLOGY

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

(2019) Rastilav Bahleda et al.   CLINICAL CANCER RESEARCH

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

(2019) Padmanee Sharma et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development.

(2019) Andrea Necchi et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure–QTc in patients with advanced or refractory solid tumors

(2019) Elodie Valade et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Management of metastatic bladder cancer

(2019) Rosa Nadal et al.   CANCER TREATMENT REVIEWS

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer

(2019) Li Wang et al.   EUROPEAN UROLOGY

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

(2019) Jonathan E. Rosenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Yohann Loriot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling

(2019) Brian D. Robinson et al.   Nature Communications

Anti–Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development

(2018) Thomas Powles et al.   Clinical Genitourinary Cancer

Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.

(2018) Yohann Loriot et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

(2018) Sumanta K. Pal et al.   Cancer Discovery

Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

(2018) Qingsong Gao et al.   Cell Reports

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

(2018) A. Gordon Robertson et al.   CELL

Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018

(2018) Marcus George Kwesi Cumberbatch et al.   EUROPEAN UROLOGY

Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway.

(2018) Markus Joerger et al.   JOURNAL OF CLINICAL ONCOLOGY

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018

(2018) Thomas W. Flaig et al.   Journal of the National Comprehensive Cancer Network

930TiPPhase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression

(2018) C N Sternberg et al.   ANNALS OF ONCOLOGY

Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites

(2018) Amin H Nassar et al.   CLINICAL CANCER RESEARCH

Fibroblast growth factor receptors as treatment targets in clinical oncology

(2018) Masaru Katoh   Nature Reviews Clinical Oncology

Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends

(2017) Sebastien Antoni et al.   EUROPEAN UROLOGY

Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors

(2017) Tomohiro Nishina et al.   INVESTIGATIONAL NEW DRUGS

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

(2017) Philippe E. Spiess et al.   Journal of the National Comprehensive Cancer Network

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

(2017) Arjun V Balar et al.   LANCET

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

(2017) Arjun V Balar et al.   LANCET ONCOLOGY

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

(2017) Timothy P.S. Perera et al.   MOLECULAR CANCER THERAPEUTICS

Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors

(2017) Sarah Bétrian et al.   JAMA Dermatology

Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope

(2016) Rafael Morales-Barrera et al.   CANCER TREATMENT REVIEWS

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)

(2016) Francesco Soria et al.   WORLD JOURNAL OF UROLOGY

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations

(2015) Jeffrey S. Ross et al.   CANCER

Targeting FGFR Signaling in Cancer

(2015) M. Touat et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

(2015) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma

(2014) Matthew I. Milowsky et al.   EUROPEAN JOURNAL OF CANCER

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

(2013) R. Dienstmann et al.   ANNALS OF ONCOLOGY

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo

(2010) F R Lamont et al.   BRITISH JOURNAL OF CANCER

Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

(2009) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY